GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 24, 2023 at 09:12: AM
via British drugmaker GSK's HIV treatment division, ViiV Healthcare, published data on Wednesday showing its long-acting HIV injection is as effective as the market-leading daily pill made by Gilead Sciences Inc.

article source
 

<



Similar threads

cafead
J&amp;J, GSK&#039;s ViiV tout switching study showing patients prefer their long-acting HIV...
Replies
0
Views
161
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
GSK&#039;s ViiV explores novel pathway to bring long-acting HIV med Cabenuva to...
Replies
0
Views
124
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
GSK&#039;s ViiV gives early look at HIV broadly neutralizing antibody&#039;s power, eyes...
Replies
0
Views
140
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
GSK&#039;s ViiV looks to future of injectable HIV treatment as long-acting PrEP decision looms
Replies
0
Views
122
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
GSK&#039;s ViiV turns to Black women&#039;s experiences in latest season of award-winning...
Replies
0
Views
149
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote